LINE
ACHAT TOTAL: 25 000 titres (~987 555,00 $ US)
- Insiders
- Marchetti Kevin Patrick
- Total bought
- $987,555
- Total sold
- —
- Last activity
- 2026-08-28
- Last synced
-
2026-09-03 09:53:14
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-01
LINE presents a compelling near-term catalyst with a Q2 2026 earnings beat, insider buying, and a new BlackRock position, but these positive signals are severely undermined by deeply distressed fundamentals — chronic…
The first sentence of the analysis written for LINE on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 15.4% | 33.0% | 32.8% | 29.5% | 30.5% | |
| Ebit Margin | 2.9% | -6.2% | 8.9% | 6.0% | 0.8% | |
| Ebitda Margin | 19.6% | 10.2% | 23.2% | 19.8% | 17.1% | |
| Operating Profit Margin | 4.7% | 6.8% | -7.5% | -6.0% | 2.4% | |
| Pretax Profit Margin | -2.1% | -15.7% | -2.1% | -1.4% | -5.6% | |
| Continuous Operations Profit Margin | -2.1% | -14.1% | -1.8% | -1.5% | -4.8% | |
| Net Profit Margin | -1.8% | -12.4% | -1.4% | -1.3% | -4.1% | |
| Bottom Line Profit Margin | -1.8% | -13.2% | -1.4% | -1.3% | -4.1% | |
| Current Ratio | 0.800 | 0.861 | 0.920 | 1.145 | 1.187 | |
| Quick Ratio | 0.707 | 0.735 | 0.795 | 1.017 | 1.049 | |
| Solvency Ratio | 0.080 | 0.024 | 0.053 | 0.049 | 0.040 | |
| Cash Ratio | 0.043 | 0.116 | 0.050 | 0.140 | 0.200 | |
| Price To Earnings Ratio | -81.395 | -15.830 | -218.324 | -269.267 | -110.658 | |
| Price To Earnings Growth Ratio | 0.921 | -0.018 | -9.357 | 4.571 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.921 | -0.018 | -9.357 | 4.571 | 0.000 | |
| Price To Earnings Diluted Ratio | -81.395 | -15.830 | -218.324 | -269.267 | -110.658 | |
| Price To Earnings Diluted Growth Ratio | 0.921 | -0.018 | -9.357 | 4.571 | 0.000 | |
| Price To Book Ratio | 0.968 | 1.295 | 3.362 | 3.296 | 3.924 | |
| Price To Sales Ratio | 1.490 | 2.095 | 3.179 | 3.455 | 4.600 | |
| Price To Free Cash Flow Ratio | 40.714 | 932.239 | 565.999 | -54.578 | -47.407 | |
| Price To Operating Cash Flow Ratio | 8.462 | 15.913 | 21.332 | 33.989 | 51.617 | |
| Debt To Assets Ratio | 0.451 | 0.369 | 0.586 | 0.576 | 0.585 | |
| Debt To Equity Ratio | 1.050 | 0.796 | 2.187 | 2.069 | 2.213 | |
| Debt To Capital Ratio | 0.512 | 0.443 | 0.686 | 0.674 | 0.689 | |
| Long Term Debt To Capital Ratio | 0.449 | 0.362 | 0.639 | 0.627 | 0.636 | |
| Financial Leverage Ratio | 2.327 | 2.160 | 3.736 | 3.592 | 3.783 | |
| Working Capital Turnover Ratio | -20.716 | -33.691 | 156.428 | 26.409 | 0.000 | |
| Operating Cash Flow Ratio | 0.609 | 0.471 | 0.583 | 0.410 | 0.315 | |
| Operating Cash Flow Sales Ratio | 0.176 | 0.132 | 0.149 | 0.102 | 0.089 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.208 | 0.017 | 0.038 | -0.623 | -1.089 | |
| Debt Service Coverage Ratio | 2.599 | 1.069 | 2.046 | 2.285 | 2.602 | |
| Interest Coverage Ratio | 0.940 | 0.670 | -0.677 | -0.765 | 0.373 | |
| Short Term Operating Cash Flow Coverage Ratio | 6.934 | 12.554 | 33.167 | 13.764 | 16.918 | |
| Operating Cash Flow Coverage Ratio | 0.109 | 0.102 | 0.072 | 0.047 | 0.034 | |
| Capital Expenditure Coverage Ratio | 1.262 | 1.017 | 1.039 | 0.616 | 0.479 | |
| Dividend Paid And Capex Coverage Ratio | 0.734 | 0.760 | 0.980 | 0.505 | 0.394 | |
| Dividend Payout Ratio | -5.480 | -0.352 | -0.597 | -2.857 | -0.968 | |
| Enterprise Value Multiple | 15.812 | 32.709 | 22.586 | 28.225 | 41.751 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.4% | ▼-17.6% | ▼-12.8% |
| Ebit Margin | 2.9% | ▲9.0% | ▲0.4% |
| Ebitda Margin | 19.6% | ▲9.3% | ▲1.6% |
| Operating Profit Margin | 4.7% | ▼-2.1% | ▲4.6% |
| Pretax Profit Margin | -2.1% | ▲13.6% | ▲3.2% |
| Continuous Operations Profit Margin | -2.1% | ▲11.9% | ▲2.8% |
| Net Profit Margin | -1.8% | ▲10.6% | ▲2.4% |
| Bottom Line Profit Margin | -1.8% | ▲11.4% | ▲2.5% |
| Current Ratio | 0.800 | ▼-0.060 | ▼-0.182 |
| Quick Ratio | 0.707 | ▼-0.029 | ▼-0.154 |
| Solvency Ratio | 0.080 | ▲0.057 | ▲0.031 |
| Cash Ratio | 0.043 | ▼-0.073 | ▼-0.067 |
| Price To Earnings Ratio | -81.395 | ▼-65.566 | ▲57.699 |
| Price To Earnings Growth Ratio | 0.921 | ▲0.939 | ▲1.697 |
| Forward Price To Earnings Growth Ratio | 0.921 | ▲0.939 | ▲1.697 |
| Price To Earnings Diluted Ratio | -81.395 | ▼-65.566 | ▲57.699 |
| Price To Earnings Diluted Growth Ratio | 0.921 | ▲0.939 | ▲1.697 |
| Price To Book Ratio | 0.968 | ▼-0.327 | ▼-1.601 |
| Price To Sales Ratio | 1.490 | ▼-0.605 | ▼-1.474 |
| Price To Free Cash Flow Ratio | 40.714 | ▼-891.525 | ▼-246.679 |
| Price To Operating Cash Flow Ratio | 8.462 | ▼-7.451 | ▼-17.800 |
| Debt To Assets Ratio | 0.451 | ▲0.083 | ▼-0.062 |
| Debt To Equity Ratio | 1.050 | ▲0.254 | ▼-0.613 |
| Debt To Capital Ratio | 0.512 | ▲0.069 | ▼-0.089 |
| Long Term Debt To Capital Ratio | 0.449 | ▲0.086 | ▼-0.094 |
| Financial Leverage Ratio | 2.327 | ▲0.166 | ▼-0.793 |
| Working Capital Turnover Ratio | -20.716 | ▲12.975 | ▼-46.402 |
| Operating Cash Flow Ratio | 0.609 | ▲0.138 | ▲0.132 |
| Operating Cash Flow Sales Ratio | 0.176 | ▲0.044 | ▲0.047 |
| Free Cash Flow Operating Cash Flow Ratio | 0.208 | ▲0.191 | ▲0.498 |
| Debt Service Coverage Ratio | 2.599 | ▲1.530 | ▲0.479 |
| Interest Coverage Ratio | 0.940 | ▲0.271 | ▲0.832 |
| Short Term Operating Cash Flow Coverage Ratio | 6.934 | ▼-5.620 | ▼-9.733 |
| Operating Cash Flow Coverage Ratio | 0.109 | ▲0.007 | ▲0.036 |
| Capital Expenditure Coverage Ratio | 1.262 | ▲0.245 | ▲0.380 |
| Dividend Paid And Capex Coverage Ratio | 0.734 | ▼-0.026 | ▲0.060 |
| Dividend Payout Ratio | -5.480 | ▼-5.127 | ▼-3.429 |
| Enterprise Value Multiple | 15.812 | ▼-16.897 | ▼-12.405 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $7.98B | $11.19B | $16.98B | $17.03B | $17.03B | |
| Enterprise value | $16.57B | $17.89B | $27.96B | $27.55B | $26.42B | |
| EV / Sales | 3.09x | 3.35x | 5.23x | 5.59x | 7.14x | |
| EV / Op. cash flow | 17.57x | 25.45x | 35.13x | 54.98x | 80.10x | |
| EV / Free cash flow | 84.55x | 1490.99x | 932.03x | -88.29x | -73.56x | |
| EV / EBITDA | 15.81x | 32.71x | 22.59x | 28.23x | 41.75x | |
| Net debt / EBITDA | 8.20x | 12.26x | 8.87x | 10.78x | 14.85x | |
| Current ratio | 0.80x | 0.86x | 0.92x | 1.15x | 1.19x | |
| Income quality | -8.35x | -0.94x | -8.29x | -6.59x | -1.87x | |
| Graham net-net | -$40 | -$42 | -$57 | -$55 | -$49 | |
| Tax burden | 85.2% | 79.0% | 70.0% | 90.0% | 74.5% | |
| Interest burden | -75.2% | 255.3% | -23.0% | -23.5% | -704.8% | |
| Working capital | -$309.0M | -$208.0M | -$109.0M | $177.3M | $195.9M | |
| Invested capital | $17.30B | $16.77B | $17.10B | $16.88B | $15.12B | |
| Return on assets | -0.5% | -3.6% | -0.4% | -0.3% | -0.9% | |
| Operating ROA | 1.3% | 1.9% | -2.1% | -1.7% | 0.0% | |
| Return on tangible assets | -0.7% | -4.7% | -0.5% | -0.5% | -1.2% | |
| Return on equity | -1.2% | -7.7% | -1.5% | -1.2% | -3.5% | |
| Return on invested capital | 1.4% | 1.9% | -2.0% | -1.7% | 0.5% | |
| Return on capital employed | 1.4% | 2.1% | -2.3% | -1.7% | 0.6% | |
| Earnings yield | -1.2% | -5.9% | -0.5% | -0.4% | -0.9% | |
| Free cash flow yield | 2.5% | 0.1% | 0.2% | -1.8% | -2.1% | |
| Capex / Op. cash flow | 79.2% | 98.3% | 96.2% | 162.3% | 208.9% | |
| Capex / Depreciation | 83.5% | 78.9% | 100.8% | 119.9% | 114.1% | |
| Capex / Sales | 13.9% | 12.9% | 14.3% | 16.5% | 18.6% | |
| SG&A / Sales | 10.7% | 10.1% | 9.4% | 8.1% | 7.8% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 2.4% | 4.0% | 0.5% | 0.3% | 0.4% | |
| Intangibles / Total assets | 23.7% | 23.9% | 24.8% | 25.0% | 25.2% | |
| Days sales outstanding | 61d | 56d | 62d | 69d | 68d | |
| Days payables outstanding | 88d | 124d | 116d | 114d | 115d | |
| Operating cycle | 73d | 76d | 80d | 86d | 89d | |
| Cash conversion cycle | -16d | -49d | -36d | -28d | -26d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-28.7%EV / Sales ▼-7.6%EV / EBITDA ▼-51.7%EV / Op. cash flow ▼-7.878Earnings yield ▲+0.047
Profitability
Return on equity ▲+0.065Return on assets ▲+0.030Return on invested capital ▼-0.005Return on capital employed ▼-0.007Operating ROA ▼-0.006Income quality ▼-7.409Tax burden ▲+0.062
Efficiency
Days sales outstanding ▲+4.613Days payables outstanding ▼-36.126Operating cycle ▼-2.777Cash conversion cycle ▲+33.349Capex / Sales ▲+0.010R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.060Net debt / EBITDA ▼-4.060Working capital ▼-101000000.000Invested capital ▲+537000000.000Intangibles / Total assets ▼-0.002
Change over 5 years
Valuation
Market cap ▼-53.1%EV / Sales ▼-56.6%EV / EBITDA ▼-62.1%EV / Op. cash flow ▼-62.525Earnings yield ▼-0.003
Profitability
Return on equity ▲+0.023Return on assets ▲+0.004Return on invested capital ▲+0.009Return on capital employed ▲+0.009Operating ROA n/aIncome quality ▼-6.476Tax burden ▲+0.107
Efficiency
Days sales outstanding ▼-7.245Days payables outstanding ▼-26.988Operating cycle ▼-16.070Cash conversion cycle ▲+10.918Capex / Sales ▼-0.047R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.387Net debt / EBITDA ▼-6.648Working capital ▼-504900000.000Invested capital ▲+2178300000.000Intangibles / Total assets ▼-0.015
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2024-09-26 | Ritchie Torres | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-01 CARNIVAL CRUISE LINE LAUNCHES CARNIVAL REWARDS™ New Program Introduces Flexible Rewards, Status Recognition, Milestone Benefits and More Ways for Guests to Unlock Meaningful Value MIAMI, Sept. 1, 2026 /PRNewswire/ -- Carnival Cruise Line launched Carnival Rewards today, a first-of-its-kind loyalty program in the cruise industry that gives guests more ways to earn rewards, achieve status and be recognized in ways that matter most to them.
- 2026-08-28 BlackRock Inc. Takes Position in Lineage, Inc. $LINE BlackRock Inc. bought a new position in shares of Lineage, Inc. (NASDAQ: LINE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 5,260,370 shares of the company''s stock, valued at approximately $227,511,000. BlackRock Inc. owned 2.31% of Lineage as of its most recent
- 2026-08-17 KARMAN LINE ACQUISITION CORP. Announces Pricing of $200 Million Initial Public Offering BOCA RATON, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- KARMAN LINE ACQUISITION CORP. (the “Company”), a special purpose acquisition company, today announced the pricing of its initial public offering of 20,000,000 units at a price of $10.00 per unit. The units are expected to be listed for trading on the Nasdaq Global Market (“Nasdaq”) under the ticker symbol “XTERU” beginning August 18, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant of the Company. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Once the securities comprising the units begin separate trading, the Company expects that its Class A ordinary shares and warrants will be listed on Nasdaq under the symbols “XTER” and “XTERW,” respectively. The offering is expected to close on August 19, 2026, subject to customary closing conditions.
- 2026-08-09 Lineage Cell Therapeutics Q2 Earnings Call Highlights Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
- 2026-08-06 Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Q2 2026 Earnings Release.
- 2026-08-05 Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript Lineage, Inc. (LINE) Q2 2026 Earnings Call Transcript
- 2026-08-05 Lineage Q2 Earnings Call Highlights Lineage NASDAQ: LINE reported second-quarter results that exceeded its internal expectations and consensus estimates as warehouse occupancy improved and cost-control efforts helped offset continued trade-related volume pressure.
- 2026-08-05 Compared to Estimates, Lineage, Inc. (LINE) Q2 Earnings: A Look at Key Metrics Although the revenue and EPS for Lineage, Inc. (LINE) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 2026-08-05 Lineage, Inc. (LINE) Beats Q2 FFO and Revenue Estimates Lineage, Inc. (LINE) came out with quarterly funds from operations (FFO) of $0.76 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to FFO of $0.81 per share a year ago.
- 2026-08-05 Lineage, Inc. Reports Second-Quarter 2026 Financial Results NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE) (the "Company"), the world''s largest global temperature-controlled warehouse REIT, today announced its financial results for the second quarter of 2026. Second-Quarter 2026 Financial Highlights Total revenue increased 0.8% to $1,361 million GAAP net loss of $(32) million, or $(0.13) per diluted common share Adjusted EBITDA decreased (1.8)% to $320 million; adjusted EBITDA margin decreased (60)bps to 23.5% AFFO decreased (6.2)% to $198 m.